Management of Patients With Treatment-Resistant Metastatic Prostate Cancer
The following is a lightly edited transcript of a teleconference recorded in December 2018. It follows up on previous prostate-cancer discussions on survivorship (Aronson WJ, Nickols NG, Neymark A, Glassman P. Coordination of care between primary care and oncology for patients with prostate cancer. Fed Pract. 2018;35[5]:S18-S23.) and first-line treatments (Aronson WJ, Graff JN, Houranieh JM, Nickols NG. Treatment and management of patients with prostate cancer. Fed Pract. 2017;34[suppl 3]:S35-S41).
Pharmacy
Julie Graff. Before we end I want to make sure that we applaud the amazing pharmacists and patient care navigation teams in the VA who do such a great job of getting veterans the appropriate treatment expeditiously and keeping them safe. It’s something that is truly unique to the VA. And I want to thank the people on this call who do this every day.
Elizabeth Hansen. Thank you Julie. Compared with working in the community, at the VA I’m honestly amazed by the ease of access to these medications for our patients. Being able to deliver medications sometimes the same day to the patient is just not something that happens in the community. It’s nice to see that our veterans are getting cared for in that manner.
Author disclosures
Dr. Solanki participated in advisory boards for Blue Earth Diagnostics’ fluciclovine PET and was previously paid as a consultant. Dr. Graff is a consultant for Sanofi (docetaxel) and Astellas (enzalutamide), and has received research funding (no personal funding)from Sanofi, Merck (pembrolizumab), Astellas, and Jannsen (abiraterone, apalutamide). The other authors report no actual or potential conflicts of interest with regard to this article.
Disclaimer
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review the complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.
